Your session is about to expire
← Back to Search
DFMO for Neuroblastoma
Study Summary
This trial is designed to study the safety and efficacy of DFMO in preventing reoccurrence of neuroblastoma.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 140 Patients • NCT02395666Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You cannot participate if you are currently taking any experimental medication.
- Group 1: DFMO twice daily
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently involved in this research program?
"At the present time, this research project is not recruiting participants. Initially posted in March 2015 and last modified on April 20th 2022, it does not appear to be open for enrollment. If you're searching for other trials, 161 studies are enrolling patients with neuroblastoma while 11 more accept subjects being treated with DFMO."
Could you provide an overview of past research endeavors that have utilized DFMO?
"First studied in 2013, the effects of DFMO have been monitored across 11 trials. Currently, a further 11 clinical studies are underway; many of these can be found in Minneapolis."
How many Canadian sites are hosting this clinical trial?
"This clinical trial is operating in 24 places, with its primary 3 sites being Children's Hospital and Clinics on Minnesota in Minneapolis, Minnesota; Children's Mercy Hospitals and Clinics in Kansas City, Missouri; and Kapiolani Medical Center for Women and Children in Honolulu, Hawaii."
Are individuals able to apply for this trial at present?
"Unfortunately, no longer are individuals being accepted into this clinical trial. It was initially posted on 1st March 2015 and has just been recently updated on 20th April 2022. However, there are still 161 studies seeking patients with neuroblastoma as well 11 trials for DFMO that need participants to participate in the research."
Is this investigation the inaugural research of its type?
"Ever since 2013, DFMO has been the subject of medical research, with a first trial sponsored by Cancer Prevention Pharmaceuticals Inc. After these initial investigations involving 1340 participants that same year led to phase 3 drug approval. Nowadays there are 11 active clinical trials for this medication conducted in 699 cities and 12 countries around the world."
Does the Food and Drug Administration recognize DFMO as a viable medical treatment?
"Our team has evaluated DFMO's safety according to the available data and assigned it a score of 2; while Phase 2 trials provide some evidence that this medicine is safe, there is no existing proof that it works."
Share this study with friends
Copy Link
Messenger